Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Selecta Biosciences

DB:1S7
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1S7
DB
$158M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Selecta Biosciences has significant price volatility in the past 3 months.
1S7 Share Price and Events
7 Day Returns
-14.8%
DB:1S7
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-36.9%
DB:1S7
-13.2%
DE Biotechs
-20.9%
DE Market
1S7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Selecta Biosciences (1S7) -14.8% -53.2% -36.1% -36.9% -87.9% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 1S7 underperformed the Biotechs industry which returned -13.2% over the past year.
  • 1S7 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
1S7
Industry
5yr Volatility vs Market
Related Companies

1S7 Value

 Is Selecta Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Selecta Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €1.61.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Selecta Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Selecta Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1S7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.22
NasdaqGM:SELB Share Price ** NasdaqGM (2020-04-03) in USD $1.83
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Selecta Biosciences.

DB:1S7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SELB Share Price ÷ EPS (both in USD)

= 1.83 ÷ -1.22

-1.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Selecta Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Selecta Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Selecta Biosciences's expected growth come at a high price?
Raw Data
DB:1S7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
10.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Selecta Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Selecta Biosciences's assets?
Raw Data
DB:1S7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.10
NasdaqGM:SELB Share Price * NasdaqGM (2020-04-03) in USD $1.83
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:1S7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SELB Share Price ÷ Book Value per Share (both in USD)

= 1.83 ÷ 0.10

18.81x

* Primary Listing of Selecta Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Selecta Biosciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Selecta Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Selecta Biosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1S7 Future Performance

 How is Selecta Biosciences expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Selecta Biosciences expected to grow at an attractive rate?
  • Unable to compare Selecta Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Selecta Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Selecta Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1S7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1S7 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 10.9%
DB:1S7 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 67.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1S7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1S7 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 165 14 -9 6
2023-12-31 79 -53 -70 6
2022-12-31 15 -82 -86 6
2021-12-31 1 -79 -85 7
2020-12-31 1 -79 -81 7
2020-04-06
DB:1S7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -51 -55
2019-09-30 1 -51 -55
2019-06-30 1 -56 -59
2019-03-31 1 -66 -62
2018-12-31 1 -59 -65
2018-09-30 0 -59 -70
2018-06-30 0 -58 -69
2018-03-31 0 -50 -66
2017-12-31 0 -52 -65
2017-09-30 3 -38 -60
2017-06-30 4 -28 -53
2017-03-31 6 -25 -46

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Selecta Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Selecta Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1S7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Selecta Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1S7 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.32 2.99 -0.67 5.00
2023-12-31 -0.39 1.28 -1.14 5.00
2022-12-31 -0.80 -0.45 -1.11 5.00
2021-12-31 -1.00 -0.46 -1.78 7.00
2020-12-31 -1.09 -0.69 -1.72 7.00
2020-04-06
DB:1S7 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.22
2019-09-30 -1.45
2019-06-30 -1.84
2019-03-31 -2.33
2018-12-31 -2.92
2018-09-30 -3.14
2018-06-30 -3.09
2018-03-31 -3.09
2017-12-31 -3.20
2017-09-30 -3.08
2017-06-30 -2.87
2017-03-31 -3.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Selecta Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Selecta Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Selecta Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1S7 Past Performance

  How has Selecta Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Selecta Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Selecta Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Selecta Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Selecta Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Selecta Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Selecta Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1S7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 6.68 -55.35 16.39
2019-09-30 0.93 -55.11 17.46 16.46
2019-06-30 0.93 -59.12 17.83 17.15
2019-03-31 0.91 -61.52 18.08 18.89
2018-12-31 0.90 -65.34 18.24
2018-09-30 0.02 -70.23 18.76 20.33
2018-06-30 0.04 -68.90 19.08 17.73
2018-03-31 0.07 -66.08 19.63 18.18
2017-12-31 0.21 -65.32 18.83
2017-09-30 3.12 -59.86 18.91 18.30
2017-06-30 4.14 -52.91 17.03 19.73
2017-03-31 6.13 -46.08 14.55 16.21
2016-12-31 8.08 -40.78 13.05 14.40
2016-09-30 7.29 -35.92 9.32 12.92
2016-06-30 7.85 -35.75 9.02 12.94
2016-03-31 7.07 -35.05 8.84 13.77
2015-12-31 6.01 -32.51 8.34 8.39
2015-09-30 4.81 -26.47 7.59 12.03
2014-12-31 3.04 -16.37 7.95 9.97
2013-12-31 1.48 -19.28 6.36 9.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Selecta Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Selecta Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Selecta Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Selecta Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Selecta Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1S7 Health

 How is Selecta Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Selecta Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Selecta Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Selecta Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Selecta Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Selecta Biosciences Company Filings, last reported 3 months ago.

DB:1S7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 8.40 18.91 89.89
2019-09-30 -4.92 20.93 34.23
2019-06-30 0.06 21.55 41.68
2019-03-31 14.82 21.47 48.42
2018-12-31 -5.42 21.39 37.40
2018-09-30 10.00 21.30 50.49
2018-06-30 24.26 21.21 66.23
2018-03-31 41.58 21.13 83.07
2017-12-31 51.81 21.04 96.56
2017-09-30 65.08 20.95 104.39
2017-06-30 78.18 10.34 112.66
2017-03-31 41.09 11.39 68.52
2016-12-31 54.96 12.04 84.14
2016-09-30 65.44 11.98 79.28
2016-06-30 68.78 11.91 84.55
2016-03-31 14.34 11.84 25.98
2015-12-31 21.28 11.86 36.46
2015-09-30 27.90 5.92 38.18
2014-12-31 6.28 7.40 16.59
2013-12-31 0.94 2.71 8.06
  • Selecta Biosciences's level of debt (225.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (116.3% vs 225.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Selecta Biosciences has sufficient cash runway for 1.7 years based on current free cash flow.
  • Selecta Biosciences has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 26% each year.
X
Financial health checks
We assess Selecta Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Selecta Biosciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1S7 Dividends

 What is Selecta Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Selecta Biosciences dividends.
If you bought €2,000 of Selecta Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Selecta Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Selecta Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1S7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1S7 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Selecta Biosciences has not reported any payouts.
  • Unable to verify if Selecta Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Selecta Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Selecta Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Selecta Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Selecta Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Selecta Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1S7 Management

 What is the CEO of Selecta Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carsten Brunn
COMPENSATION $5,605,148
AGE 48
TENURE AS CEO 1.3 years
CEO Bio

Dr. Carsten Brunn, Ph.D. serves as President, Chief Executive Officer and Director of Selecta Biosciences, Inc. since December 1, 2018. Dr. Brunn served as President of Pharmaceuticals Business - Americas at Bayer Aktiengesellschaft and Bayer Corporation since January 17, 2017. Previously, Dr. Brunn served as a Head of Bayer's Pharmaceuticals Commercial Operations in Japan, a role he held since 2013. He joined Bayer in 2011 as Global Head of Primary Care based in Beijing, China. Prior to joining Bayer, Dr. Brunn held a number of senior leadership roles at companies including Eli Lilly, Novartis and Bausch & Lomb in Europe, Asia and the United States. He served as the Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing 24 R&D-based innovative pharmaceutical companies in Japan. He currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO). Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Science. In addition, he studied at the University of Washington under a research scholarship and later received his PhD in Chemistry from the University of Hamburg in Germany. He completed his executive education at the London Business School.

CEO Compensation
  • Insufficient data for Carsten to compare compensation growth.
  • Carsten's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Selecta Biosciences management team in years:

1.2
Average Tenure
52.5
Average Age
  • The average tenure for the Selecta Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Carsten Brunn

TITLE
CEO, President & Director
COMPENSATION
$6M
AGE
48
TENURE
1.3 yrs

Stephen Smolinski

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
54
TENURE
2.5 yrs

Ulrich von Andrian-Werburg

TITLE
Co-Founder and Co-Chair of the Scientific Advisory Board
TENURE
13.3 yrs

Bradford Dahms

TITLE
CFO, Principal Financial Officer & Principal Accounting Officer
AGE
31
TENURE
0.6 yrs

Lloyd Johnston

TITLE
COO and Senior VP of Research & Development
COMPENSATION
$1M
AGE
51
TENURE
6.3 yrs

Takashi Kishimoto

TITLE
Chief Scientific Officer
COMPENSATION
$471K
AGE
59
TENURE
8.8 yrs

Elona Kogan

TITLE
General Counsel & Corporate Secretary
AGE
50
TENURE
1.1 yrs

Horacio Plotkin

TITLE
Head of Clinical Development
AGE
54
TENURE
1.1 yrs

Peter Traber

TITLE
Interim Chief Medical Officer
AGE
64
TENURE
0.1 yrs

Ann Donohue

TITLE
Controller
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Selecta Biosciences board of directors in years:

2.8
Average Tenure
54.5
Average Age
  • The average tenure for the Selecta Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Carrie Cox

TITLE
Chairman
AGE
61
TENURE
0.4 yrs

Carsten Brunn

TITLE
CEO, President & Director
COMPENSATION
$6M
AGE
48
TENURE
1.3 yrs

Ulrich von Andrian-Werburg

TITLE
Co-Founder and Co-Chair of the Scientific Advisory Board

Tim Barabe

TITLE
Independent Director
COMPENSATION
$144K
AGE
66
TENURE
3.8 yrs

Pat Zenner

TITLE
Lead Director
COMPENSATION
$156K
AGE
72
TENURE
1.8 yrs

Amir Nashat

TITLE
Independent Director
COMPENSATION
$149K
AGE
46
TENURE
12.3 yrs

Glenn Dranoff

TITLE
Member of Scientific Advisory Board

Peter Howley

TITLE
Member of Scientific Advisory Board

Dennis Kasper

TITLE
Member of Scientific Advisory Board

Aymeric Sallin

TITLE
Independent Director
COMPENSATION
$134K
AGE
45
TENURE
12.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Selecta Biosciences individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Mar 20 Buy Timothy Barabe Individual 17. Mar 20 17. Mar 20 5,000 €1.82 €9,105
16. Aug 19 Buy Timothy Springer Individual 14. Aug 19 14. Aug 19 10,000 €1.56 €15,628
15. Aug 19 Buy Timothy Barabe Individual 13. Aug 19 13. Aug 19 10,000 €1.54 €15,368
X
Management checks
We assess Selecta Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Selecta Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1S7 News

Simply Wall St News

1S7 Company Info

Description

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company’s lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.

Details
Name: Selecta Biosciences, Inc.
1S7
Exchange: DB
Founded: 2007
$146,588,267
86,420,195
Website: http://selectabio.com
Address: Selecta Biosciences, Inc.
480 Arsenal Way,
Watertown,
Massachusetts, 02472,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SELB Common Stock Nasdaq Global Market US USD 22. Jun 2016
DB 1S7 Common Stock Deutsche Boerse AG DE EUR 22. Jun 2016
Number of employees
Current staff
Staff numbers
39
Selecta Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:27
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.